Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma by Alhasan SF et al.
Sulfatase-2: a prognostic biomarker and
candidate therapeutic target in patients with
pancreatic ductal adenocarcinoma
Sari F Alhasan1,6, Beate Haugk2,6, Laura F Ogle1, Gary S Beale1, Anna Long2, Alastair D Burt2,3,
Dina Tiniakos2,4, Despina Televantou1,2, Fareeda Coxon5, David R Newell1, Richard Charnley5 and
Helen L Reeves*,1,5
1Northern Institute for Cancer Research, Paul O’Gorman Building, The Medical School, Framlington Place, Newcastle University,
Newcastle upon Tyne NE2 4HH, UK; 2Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals
NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK; 3School of Medicine, Eleanor Harrald Building, Frome Road,
The University of Adelaide, Adelaide, 5000 South Australia, Australia; 4Institute of Cellular Medicine, The Medical School,
Framlington Place, Newcastle University, Newcastle upon Tyne NE2 4HH, UK and 5Hepatopancreatobiliary multidisciplinary team,
Freeman Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK
Background: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. Its poor
prognosis is attributed to late detection and limited therapeutic options. Expression of SULF2, an endosulfatase that modulates
heparan sulfate proteoglycan 6-O-sulfation and is reportedly tumourigenic in different types of cancer, was investigated.
Methods: SULF2 expression was determined immunohistochemically in archival surgical resection tissue sections from 93 patients
with a confirmed histological diagnosis of PDAC between 2002 and 2008 followed for a median of 9 years. Relationships with
clinico-pathological parameters and patient survival were explored.
Results: The majority of PDACs showed positive SULF2 staining in tumour cells and intratumoural or tumour-adjacent stroma.
Greater than 25% SULF2-positive tumour cells was present in 60% of cancers and correlated with tumour stage (P¼ 0.002) and
perineural invasion (P¼ 0.024). SULF2 intensity was scored moderate or strong in 81% of cancers and positively correlated with
vascular invasion (P¼ 0.015). High SULF2 expression, defined as 450% SULF2-positive tumour cells and strong SULF2 staining,
was associated with shorter time to radiological progression (P¼ 0.018, HR 1.98, CI 1.13–3.47). Similarly, by multivariate analysis,
high SULF2 expression was independently associated with poorer survival (P¼ 0.004, HR 2.10, CI 1.26–3.54), with a median survival
of 11 months vs 21 months for lower PDAC SULF2.
Conclusions: Elevated SULF2 in PDAC was associated with advanced tumour stage, vascular invasion, shorter interval to
radiological progression and shorter overall survival. SULF2 may have roles as a prognostic biomarker and as a therapeutic target
for patients with PDAC.
Each year, B8800 people are diagnosed with pancreatic ductal
adenocarcinoma (PDAC) in the UK (Cancer Research UK (Cancer
Statistics)). A significant proportion of cancer-related death is
attributed to PDAC (Siegel et al, 2012) with a 5-year survival rate
in the region of 6% (DeSantis et al, 2014). PDAC is asymptomatic
in early stages and its poor prognosis is attributed to late detection,
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as well as the aggressive nature of the disease (Chrystoja et al,
2013). Consequently, only 10–15% of those affected are candidates
for surgical resection, with a 5-year survival post resection of just
10–25% owing to frequent regional invasion and distant micro-
metastases at the time of resection (Heinemann and Boeck, 2008).
The current palliative chemotherapy regimens for those with later
stage disease include gemcitabine with or without nab-paclitaxel,
or FOLFIRINOX and provide modest benefit with a median overall
survival of o1 year (Conroy et al, 2011; Thota et al, 2014).
Clinically useful biomarkers which inform prognosis or aid
treatment stratification for those with PDAC are presently lacking.
The contribution of extracellular microenvironment (ECM) to the
development and progression of PDAC is recognised (Apte et al,
2015), as is a role for the pro-angiogenic vascular endothelial
growth factor (VEGF), which is expressed in 490% of cases, and
associated with both liver metastases and shorter survival of
patients (Seo et al, 2000). ECM interactions with angiogenic as well
as proliferative signalling pathways are closely regulated by
heparan sulfate proteoglycans (HSPGs). VEGF is one of the
HSPG-bound proteins, which include other ligands relevant to
PDAC progression such as FGF-1 and FGF-2, Wnts and ECM
components such as collagens, fibronectin and laminin which are
present in PDAC stroma. The heparan sulfate (HS) chains of
HSPGs are rich in uronic acid moieties and sulfate groups that are
negatively charged, producing binding sites for growth factors,
receptors and ECM molecules. Charge, and therefore sequestration
vs release of growth factors, as well as orientation and binding
affinity, are regulated by the degree of sulfation – particularly at the
6-O position of HS chains (Pye et al, 1998, 2000; Ai et al, 2003).
6-O-Sulfation is in turn regulated by sulfotransferases which add
sulfate groups and the extracellular endosulfatases, sulfatase-1
(SULF1) and sulfatase-2 (SULF2), which remove them (Morimoto-
Tomita et al, 2002; Saad et al, 2005; Staples et al, 2011).
SULF2 has been reported to be upregulated and to have a
candidate oncogenic role in a number of cancers, including
glioblastoma, liver, lung, gastric, oesophageal and prostate cancers
(Hur et al, 2012; Lai et al, 2008, 2010; Lemjabbar-Alaoui et al, 2010;
Lui et al, 2012; Phillips et al, 2012). In PDAC, Nawroth et al (2007)
have previously reported an increase in SULF2 mRNA in cell lines
and increased SULF2 protein expression relative to non-tumour
tissues expression in a small number of cases. shRNA-mediated
SULF2 knockdown or transfection with a catalytically inactive
dominant form of SULF2 enzyme in 3 PDAC cell lines reduced cell
growth in vitro and tumourigenicity in vivo (Nawroth et al, 2007).
In this study, we have assessed SULF2 as a candidate
immunohistochemical prognostic biomarker in a cohort of 93
patients who underwent PDAC resection. In the majority of cases
SULF2 was overexpressed in PDAC cells, with the percentage of
positive cells correlating with tumour stage, and the SULF2
intensity (SI) correlating with vascular invasion. Combining
percentage of positive cells and SI, high-PDAC SULF2 was
associated with vascular invasion, a shorter time to radiological
progression and poorer overall survival.
MATERIALS AND METHODS
Patient cohort. As part of a pilot study, SULF2 expression was
assessed in formalin-fixed paraffin-embedded tissues (FFPE) from
19 patients undergoing resection for PDAC and consenting to the
use of their tissues for research projects, governed by the Newcastle
upon Tyne Hepatopancreatobiliary Research Tissue bank. The data
presented include these cases, in combination with data generated
subsequently from a larger retrospective series (an additional
74 cases), exploring SULF2 expression in archived cases from
patients with a confirmed histological diagnosis PDAC. Study of
the retrospective case series was approved by the Newcastle
and North Tyneside Regional ethics committee (REC approval
11/H0908/02) on 03 March 2011. The selection interval was from
2002 to 2008 and the REC waived the need for informed consent.
Patient confidentiality was respected at all times and analyses were
on code-linked anonymised data sets. The Newcastle upon Tyne
NHS Foundation Trust Research and Development department
approved this project.
The study is classed as a retrospective case series, including
patients undergoing resection with curative intent, in whom a
diagnosis of PDAC was histologically confirmed. Additional
inclusion criteria included the availability of FFPE blocks for
study. Patients with known distant metastases at the time of
resection were excluded, as were those with histologically benign
disease or cholangiocarcinoma.
Clinico-pathological information, including Union for Interna-
tional Cancer Control tumour node metastases (TNM) stage,
tumour grade, vascular, lymphatic and perineural invasion, lymph
node status, resection margin status, time to progression (TTP)
and patient survival, was collected from histopathology reports,
radiology reports and patient records. Patient demographics and
clinico-pathological data are shown in Table 1. The patients were
followed-up for a median of 9.4 (range 6.1 to 12.9) years until
31 December 2014.
Immunohistochemistry. SULF2 immunohistochemistry was
performed on a Benchmark Ultra autostainer (Ventana, Tucson,
AZ, USA) using anti-SULF2 antibody (catalogue number
MCA5692GA, AbD Serotec, Oxford, UK) at a dilution of 1:150.
In brief, the tissue sections were incubated in primary antibody for
32min following heat-induced epitope retrieval using CC1 buffer
(Ventana) for 64min at 100 1C. Detection and visualisation was
achieved using an OptiView IHC DAB Detection Kit and 4min of
OptiView Amplification (Ventana). Control cases without primary
antibody confirmed an absence of non-specific staining. Examples
are included in Supplementary Figure 1.
Scoring method. An expert pancreatic pathologist (BH) blinded
to patient outcome assessed the SULF2-immunostained slides
at  100 magnification. The percentage of SULF2-positive
carcinoma cells was semi-quantitatively assessed with a score from
0–4 (0¼ no carcinoma cells positive, 1¼ 1–25% carcinoma
cells positive, 2¼ 26–50% carcinoma cells positive, 3¼ 51–75%
carcinoma cells positive and 4¼ 76–100% carcinoma cells
positive). The SULF2-specific SI was assessed with a score from
0–3 (0¼ no staining, 1¼weak, 2¼moderate, 3¼ strong). Repre-
sentative cases for each score are shown in Figure 1. If a range of
SI was noted the predominant score was used. The semi-
quantitative score of SULF2-positive PDAC cells and the intensity
score were added and a summative combined score (range 0–7)
was created for each case. In addition, the extent of stromal
staining within the tumour and outside the tumour was scored
from 0 to 2 (0¼ no staining, 1¼ focal staining, 2¼ extensive
staining). Staining of benign and dysplastic epithelium or of tissues
unrelated to the tumour was recorded. Presence of endothelial
staining was recorded on all cases as an internal positive control.
A second experienced pathologist (DT) also blinded to patient
outcome, evaluated 10 random SULF2-immunostained slides
(B10% of cases). Inter-observer agreement assessed by the Kappa
measure was very good for percentage of SULF2þ ve tumour cells
(0.75) and perfect (kappa statistic 1) for SULF2 SI.
Statistical analysis. All statistical analyses were conducted using
SPSS statistical package (IBM, version 22). Percentage of SULF2-
positive cells and SI were treated as ordinal categorical variables.
To identify relationships between percentage of SULF2-positive
cells or SI with clinico-pathological features, cross-tabulation and
w2-tests were performed. The Monte Carlo correction was applied
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to groups with fewer than 5 cases. To explore factors associated
with TTP or survival, univariate Cox regression was conducted.
Only significantly associated factors were then analysed using
multivariate Cox regression. Median TTP and survival times
were calculated using Kaplan–Meier survival analysis. Missing data
were excluded from statistical studies. Where analyses were
performed on o93 cases, (e.g. TTP) numbers in the analysis are
stipulated in the text.
RESULTS
Demographic data for the case series studied. Details of the case
series of 93 patients undergoing elective curative surgery for PDAC
are summarised in Table 1. The median age was 65 years and 53
were male. The vast majority (92/93) underwent a Whipples’
pancreatoduodenectomy for tumours in the head or neck of the
pancreas. In one case the tumour was in the body and a total
pancreatectomy was performed. None of the patients received pre-
operative chemotherapy. The series did not include patients with
known metastatic disease and 70/93 were classed as having TNM
stage 3 disease. Similarly, 61/93 tumours were graded as poorly
differentiated, with the majority having vascular, perineural or
lymphatic invasion (Table 1). Forty-six patients (50%) received
adjuvant chemotherapy. The commonest adjuvant regime
(36 patients) was fluorouracil (5FU) and folinic acid, either as
the standard of care or as part of the ESPAC III trial. Similarly, six
patients received adjuvant gemcitabine. One patient received the
DNA methyl transferase inhibitor MG98, another received
capecitabine, whereas in two patients, the adjuvant regime was
not documented. Thirty two of 88 patients were documented as
receiving palliative second-line chemotherapy, most often gemci-
tabine, whereas two patients entered clinical trials. As a number of
patients follow-up palliative care was outside of our tertiary referral
centre, TTP was recorded as first documented ‘radiological’
progression. Consequently the data set was skewed towards those
patients fit enough to undergo active monitoring, with analyses on
progression being limited to the 67 patients in whom this clearly
defined end point was available. Survival data were available in all
93 patients.
Elevated SULF2 expression was common in PDAC and the
percentage of cells positive correlated with tumour stage. SULF2
was consistently identified in endothelial cells and relatively weak
expression also observed in benign atrophic ductal epithelium.
Weak-to-moderately intense cytoplasmic staining was occasionally
observed in dysplastic epithelial cells of PanINs, in islet and acinar
cells, periductal glands and benign ductal epithelial cells. Examples
of these are shown in Supplementary Figure 1, as is variable
staining that was present in lymph node sinuses, adipocytes and
inflammatory cells. In contrast, expression of SULF2 in PDAC was
frequently of greater intensity (Figure 1). In the PDAC cells, SULF2
was observed in the cytoplasm with a granular quality. Focal
membranous staining was identified in tumours with clear cell
morphology. Sixty per cent (56 out of 93) of PDACs contained
425% of cells positively stained for SULF2. A summary of the
immunohistochemical results is shown in Table 1.
The percentage of SULF2-positive tumour cells correlated
significantly with tumour stage (P¼ 0.002), the majority (16 out
of 22; 73%) of cases with 475% tumour cells positive being stage
T3, with local invasion. The percentage of SULF2-positive PDAC
cells also correlated with perineural invasion (P¼ 0.024).
Cytoplasmic SULF2 expression in intratumoural stromal
fibroblasts was either focal or marked in 69% (64 out of 93) of
PDAC. SULF2 was also evaluated in the stroma outside the
tumours and similarly showed either focal or marked staining in
the majority of cases (76 out of 93; 82%). Stromal expression of
SULF2 did not correlate with either PDAC grade or stage.
SULF2 intensity in PDAC was positively associated with the
presence of vascular invasion. In all, 81% (75 out of 93) of
cancers showed moderate or strong intensity of SULF2 expression.
Table 1. Clinico-pathological variables and SULF2 scores in
patients with PDAC
Patient characteristics Number
Total 93
Age (years, median) 65.3
Sex (female:male) 40:53
Tumour stage
T1: tumour within pancreas o2 cm 3
T2: tumour within pancreas 42 cm 19
T3: local invasion 70
T4: distant or large vessel invasion 1
Resection (R0:R1) 28:65
Lymph nodes ( ve:þ ve) 8:85
Tumour grade
Well differentiated 1
Moderately differentiated 31
Poorly differentiated 61
Vascular invasion (no:yes) 16:77
Perineural invasion (no:yes) 2:91
Lymphatic invasion (no:yes) 33:60
Lymph nodes positive 8:85
Tumour site
Head of pancreas/neck/uncinate 89/2/1
Neck and body 1
Adjuvant chemotherapy
None 47
5FU regime 36
Gemcitabine 6
Other (defined in text) 4
Palliative second-line chemotherapy 32/56
Survival (median months) 16.5
SULF2 scoring
Percentage SULF2-positive tumour cells
0¼ 0% 3
1¼ 1–25% 34
2¼ 26–50% 17
3¼ 51–75% 17
4¼ 75–100% 22
SULF2 staining intensity
0¼None 3
1¼Weak 15
2¼Moderate 38
3¼ Strong 37
SULF2 combined score
0 3
1 0
2 9
3 8
4 35
5 13
6 13
7 12
SULF2 tumour stroma
None 29
Focal 54
Marked 10
SULF2 stroma outside
None 17
Focal 48
Marked 28
Abbreviations: R¼ resection margins; R0¼ negative resection margins; R1¼microscopic tumour
infiltration (that is, tumour cells present within 1mm of the resection margin); SULF¼ sulfatase.
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The intensity correlated significantly with the presence of vascular
invasion (P¼ 0.015).
The SULF2 combined score correlated with the presence of
vascular invasion. The combined SULF2 IHC score of percentage
cells positive and the level of intensity, as shown in Table 1,
correlated significantly with the presence of vascular invasion
(P¼ 0.026, Pearson’s w2, linear by linear association).
High-PDAC SULF2 was associated with a shorter time to
radiological progression. Radiological TTP was documented in
67 out of 93 (62%), with the median TTP being 11.6 months.
One factor associated with radiological TTP was lymph node
positivity (P¼ 0.007, HR 4.15, CI 1.49–11.58). Age, sex, tumour
grade, tumour stage, resection margin status, vascular invasion,
lymphatic invasion and perineural invasion had no significant
impact on TTP in this relatively small series. Considering the
SULF2 immunohistochemistry (IHC) scores applied, both ‘475%
PDAC cells SULF2 positive’ or SULF2 SI scored as ‘strong’, were
associated with significantly shorter TTP. Combining the IHC
scores, as shown in Table 1, identified those cases with a combined
score of 6 or 7 as having a poorer outcome. The median TTP was 8
months in this combined group, vs 13 months in combined groups
scoring 0–5, as shown in Supplementary Figure 2 (P¼ 0.018,
HR 1.98, CI 1.13–3.47). Both lymph node metastasis and the
combined SULF2 score (groups 0–5 vs 6–7), were independently
associated with a shorter TTP (lymph nodes positive P¼ 0.006,
HR 4.28, CI 1.53–12; high SULF2 P¼ 0.014, HR 2.05, CI 1.16–3.63,
multivariate Cox regression; Supplementary Table 1).
Of the 67 cases with documented radiological TTP, 36 received
adjuvant chemotherapy. Adjuvant chemotherapy had no signifi-
cant impact on radiological TTP. Standard histopathological
A
PDAC 0%; SI 0; CS 0
200 µm 200 µm
200 µm 200 µm
200 µm 200 µm
200 µm 200 µm
PDAC 76–100%; SI 1; CS 5
PDAC 76–100%; SI 2; CS 6 PDAC 76–100%; SI 3; CS 7
PDAC 1–25%; SI 3; CS 4
PDAC 26–50%; SI 2; CS 4
PDAC 51–75%; SI 3; CS 6
B
C
D
E
F
G
H
Figure 1. SULF2 expression in pancreatic ductal adenocarcinoma. Representative immunohistochemical images of PDAC cases showing different
percentages of SULF2-positive tumour cells (0–100%) and SI of SULF2 in tumour cells. SI 0: none, SI 1: weak, SI 2: moderate, SI 3: strong staining.
(A) shows endothelial cell SULF2-positivity used as internal positive control. CS¼ combined SULF2 score.
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features were not associated with response to chemotherapy.
However, the percentage of SULF2-positive PDAC cells trended
towards significantly shorter TTP (P¼ 0.067, HR 1.28, CI 0.98–1.66),
as did SI of PDAC cells (P¼ 0.062, HR 1.58, CI 0.98–2.54). High
SULF2 using the combined IHC SULF2 score was associated with a
median TTP of 10.8 months vs 15.5 months for those with lower
SULF2 (P¼ 0.013, HR 2.76, CI 1.24–6.17).
High-PDAC SULF2 was significantly associated with shorter
overall survival. The overall mortality during the period of
follow-up was 94% (87 out of 93), with a median of 16.5 months
post resection until death (range 0.3–148, s.d. 30). Factors
significantly associated with survival post resection included age,
lymph node metastasis and receipt of adjuvant chemotherapy, as
assessed by univariate Cox regression analysis (Table 2). Regarding
SULF2, those cases with 475% of PDAC cells positive had a
poorer outcome, as did those cases with strong SI compared with
cases without SULF2 expression (Table 2). PDAC with a combined
SULF2 score 6 or 7 had a significantly poorer overall survival
(Table 2). Comparing combined groups 0–5 vs 6–7, the median
Table 2. Factors associated with survival
Variable n Univariate analysis Multivariate analysis
P value HR 95% CI P value HR 95% CI
Age (median 65.3 years) 93 0.031* 1.03 1.00–1.05 0.462 1.01 0.99–1.04
Sex (male/female) 53/40 0.573 1.13 0.74–1.73 Not included
PDAC TNM stage
1¼Within pancreas o2 cm 3 0.595 Not included
2¼Within pancreas 42 cm 19 0.299 2.17 0.50–9.38
3¼ Local invasion 70 0.217 2.44 0.59–9.99
4¼Distant spread 1 0.268 3.92 0.35–43.9
PDCA grade
Well 1 0.254 Not included
Moderate 31 0.676 1.53 0.21–11.3
Poor 61 0.443 2.17 0.30–15.8
Resection margin (R0/R1) 28/65 0.247 1.32 0.83–2.10 Not included
Vascular invasion (no/yes) 16/77 0.170 1.49 0.84–2.65 Not included
Perineural invasion (no/yes) 2/91 0.128 4.66 0.65–33.6 Not included
Lymphatic invasion (no/yes) 33/60 0.208 1.33 0.85–2.09 Not included
Lymph nodes þ ve (no/yes) 8/85 0.011* 3.28 1.31–8.19 0.003** 4.31 1.65–11.28
Adjuvant therapy (no/yes) 47/46 0.012* 0.58 0.38–0.89 0.009** 0.50 0.30–0.84
Palliative chemotherapy 32/56 0.88 0.68 0.43–1.06 Not included
Percentage of PDAC SULF2þ ve
0 3 0.123 Not included
1–25 34 0.057 6.94 0.95–51.0
26–50 17 0.080 6.12 0.81–46.5
51–75 17 0.084 5.99 0.79–45.6
76–100 22 0.024* 10.3 1.35–76.3
SULF2 intensity
None 3 0.008** (0.066)
Weak 15 0.045* 7.96 1.04–60.7 (0.114) (5.31) (0.67–42.0)
Moderate 38 0.103 5.25 0.72–38.5 (0.174) (4.03) (0.54–30.1)
Strong 37 0.022* 10.4 1.41–76.2 (0.058) (7.04) (0.93–53.0)
Combined SULF2 score
0 3 0.028* (0.084)
2 9 0.066 6.97 0.88–55.3 (0.164) (4.49) (0.54–37.3)
3 8 0.084 6.33 0.78–51.2 (0.211) (3.84) (0.47–31.7)
4 35 0.055 7.04 0.96–51.7 (0.124) (4.84) (0.65–36.3)
5 13 0.127 4.94 0.63–38.4 (0.194) (3.97) (0.50–31.9)
6 13 0.040* 8.47 1.10–65.3 (0.089) (6.00) (0.76–47.3)
7 12 0.006** 17.9 2.27–142.3 (0.021)* (11.65) (1.44–94.1)
Combined SULF2 score
0–5 (lower) vs 6–7 (high) 68/25 0.002** 2.21 1.35-3.61 0.004** 2.10 1.26-3.54
Tumour stromal SULF2
None 29 0.861 Not included
Focal 54 0.644 1.12 0.70–1.78
Marked 10 0.647 1.19 0.57–2.46
Stromal SULF2 (outside)
None 17 0.047* 0.377
Focal 48 0.103 0.62 0.35–1.10 0.700 1.14 0.59–2.17
Marked 28 0.775 1.09 0.59–2.01 0.224 1.51 0.78–2.91
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; PDAC¼pancreatic ductal adenocarcinoma; SULF¼ sulfatase; TNM¼ tumour node metastases. The multivariate Cox regression
analysis included variables (highlighted in bold) with a P valueo0.05 in univariate analyses. The combined bivariate SULF2 score comparing low (0–5) vs high (6–7) was entered into the analysis
shown. Data in brackets show similar multivariate analyses entering either SI score or combined SULF2 score with ordinal groups instead. For categorical variables, the comparator was the first
listed variable. HR and 95% lower and upper CI are shown for all variables. *Po0.05; **Po0.01.
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patient survival was 21 months vs 11 months, respectively
(P¼ 0.002, HR 2.21, CI 1.35–3.61), as shown in Figure 2A.
Multivariate Cox regression analysis, including age, lymph node
metastasis, receipt of adjuvant therapy, combined SULF2 IHC
score 0–5 vs 6–7 and stromal SULF2 outside the tumour is shown
in Table 2. The presence of lymph node metastasis and high SULF2
expression were independently associated with a poorer survival,
whereas receipt of adjuvant chemotherapy was associated with
improved survival.
In the subgroup of patients who received adjuvant chemother-
apy (n¼ 46), age, sex and tumour features had no impact on
survival. Again, however, higher SULF2-positive PDAC cells or
strong SULF2 SI were associated with poorer outcomes. Using the
combined IHC score, median survival was 25 months in those with
lower SULF2 (score 0–5) vs 12 months in those with a high SULF2
(score 6–7; P¼ 0.001, HR 3.23, CI 1.59–6.57) as shown in
Figure 2B.
DISCUSSION
The development of personalised or precision medicine for cancer
therapy requires the discovery, qualification and clinical use of
prognostic and predictive biomarkers. In PDAC the most common
driver genes with recurrent mutations; KRAS, SMAD4, TP53 and
CDKN2A/p16, cannot currently be exploited by available targeted
therapies. Whole-genome sequencing has identified new candi-
dates which may be druggable, but at low individual prevalence
(Waddell et al, 2015). Hence predictive biomarkers that can be
used to select specific treatments for individual patients have not
had a major impact on the management of the disease, with
systemic treatment being limited to single agent (e.g., gemcitabine)
or combination (e.g., FOLFIRINOX) cytotoxic drug therapy.
The major focus for biomarker discovery in PDAC has therefore
been the identification of novel prognostic biomarkers to inform
clinical decision making. For example, to identify poor prognosis
patients that might be suitable for experimental therapy in the
primary setting, and those with a relatively favourable prognosis in
whom more aggressive conventional treatments may be appro-
priate. A large number of conventional clinical, circulating and
pathological factors (Giovinazzo et al, 2012; Winter et al, 2013;
Bilici, 2014; Jazieh et al, 2014; Lamarca and Feliu, 2014), as well as
genomic and proteomic parameters (Marengo and Robotti, 2014),
have been the subject of biomarker discovery research in PDAC.
However, the glycoprotein CA19–9, the only FDA approved
biomarker for PDAC, is the sole factor in widespread routine
clinical use. Serum CA19–9 has utility as a diagnostic, prognostic
and surrogate response biomarker, but it has well known
limitations and its precise value in these settings remains the
subject of debate (Bilici, 2014; Jazieh et al, 2014).
Thus far, meta-analyses of immunohistochemical prognostic
biomarker studies in PDAC have identified VEGF levels (Ansari
et al, 2011; Smith et al, 2011), consistent with a role for the growth
factor in tumour angiogenesis and hence progression and
prognosis. More recently a meta-analysis assessing expression of
the chemokine receptor CXCR4 supported an association between
metastatic disease and overall survival in patients with PDAC
(Krieg et al, 2015). Both of these prognostic biomarkers offer links
to the molecular and cellular pathology of PDAC in a way that
could ultimately be exploited therapeutically. As yet, however,
these hopes have not been realised and there remains a need for
additional prognostic biomarkers, preferably ones which may be
predictive of responses to novel therapies.
Building on a previous study reporting an increase in SULF2
detected immunohistochemically in 4 of 7 patient PDAC samples
relative to non-tumour tissues (Nawroth et al, 2007), the current
study has identified expression of the extracellular endosulfatase
SULF2 as poor prognostic biomarker in PDAC that is related
to tumour stage, vascular invasion, radiological progression
and overall survival. By controlling the degree of sulfation of
extracellular HSPGs, and hence growth factor binding and
signalling, SULF2 can regulate a number of growth factors
that have been implicated in PDAC pathobiology, notably
VEGF, Wnts and TGF-b (Nawroth et al, 2007; Rosen and
Lemjabbar-Alaoui, 2010). Importantly, SULF2 is at the interface
between the PDAC cell and the tumour microenvironment,
and the importance of local tumour-host cell interactions in
cancer biology is increasingly recognised. Hence the biological
function of SULF2, its involvement in pathways of known
importance in PDAC pathogenesis and evidence that SULF2 is
a prognostic biomarker, presented here, all identify this enzyme
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Figure 2. High SULF2 in pancreatic ductal adenocarcinoma is
associated with poorer survival. Kaplan–Meier survival plots show (A)
cumulative survival of patients with high SULF2 expression compared
with patients with lower SULF2 expression. (B) Cumulative survival of a
subset of PDAC patients receiving adjuvant chemotherapy. High SULF2
equates to cases with a percentage cells positive and SI combined
score of 6–7, vs low SULF2 (scores 0–5).
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as a factor that has potential as both a biomarker and a
therapeutic target.
Target validation data in PDAC (Nawroth et al, 2007),
as well as in other tumour types (Rosen and Lemjabbar-Alaoui,
2010), are consistent with SULF2 representing a key signalling
node that could be exploited therapeutically. Inhibitors of SULFs
are now being described (Schelwies et al, 2010; Miller et al, 2015)
and, once these have been developed to the stage where they
are suitable for cell-based and preferably in vivo studies,
the therapeutic potential of SULF2 inhibition can be explored.
The data presented in this study is generated from a relatively
small retrospective case series, which is a limitation. However,
the pre-clinical data generated using molecular genetic
approaches in PDAC models are compelling (Nawroth et al,
2007) and, in conjunction with the demonstration in the
current study that SULF2 expression is a poor prognostic
biomarker, identifies SULF2 as a priority area for further PDAC
research.
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